Dr. Don S. Dizon, MD
Medical Oncology (Medical Oncology Physician)
101 Dudley St
Providence, RI 02905
Who else practices at this address →
Providence County includes mental health (6% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Rochester School of Medicine and Dentistry (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 68
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Rochester School of Medicine and Dentistry
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 222651
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tufts Medical Center Boston, MA
Medical groups
- Pratt Medical Group Inc (286 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 68
- Services billed
- 190
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 103 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 28 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Providence, RI | 37 |
| Prochlorperazine Maleate Other prescribers in Providence, RI | 28 |
| Dexamethasone Other prescribers in Providence, RI | 25 |
| Lynparza (olaparib) | 20 |
| Tamoxifen Citrate Other prescribers in Providence, RI | 13 |
| Zejula (niraparib tosylate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $6,467 in total to this clinician.
| Tersera Therapeutics LLC | $4,188 |
|---|---|
| Stemline Therapeutics Inc. | $1,560 |
| AstraZeneca UK Limited | $500 |
| Novocure Inc. | $138 |
| Pfizer Inc. | $80.75 |
| Consulting Fee | $5,560 |
|---|---|
| Food and Beverage | $499 |
| Travel and Lodging | $408 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tersera Therapeutics LLC Sep 26, 2025 | Consulting Fee Zoladex · Oncology | $2,000 |
| Stemline Therapeutics Inc. Dec 19, 2025 | Consulting Fee Orserdu · Oncology | $1,560 |
| Tersera Therapeutics LLC Oct 13, 2025 | Consulting Fee Margenza · Oncology | $1,500 |
| AstraZeneca UK Limited Jan 16, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $500 |
| Tersera Therapeutics LLC Sep 26, 2025 | Travel and Lodging Zoladex · Oncology · travel to Chicago, IL · in-kind | $270 |
| Tersera Therapeutics LLC Sep 26, 2025 | Travel and Lodging Zoladex · Oncology · travel to Chicago, IL | $138 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $20,546 in research payments for these studies, mostly to the institutions running them.
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Eli Lilly and Company · Active, not recruiting · NCT04188548
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.